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Abstract 
Background/Aims: We have previously reported that the application of sphingomyelin-based 
liposomes (SM-L) to a three-dimensional cultured skin model increase the content of ceramides 
NS, NP, AS and AP. However, the mechanism responsible for these increased ceramide levels 
was not identified.  
Methods: SM-L and sphingomyelinase (SMase) were combined and incubated at 37 °C for 24 h. 
SM-L were also applied to three-dimensional cultured skin for 24 h and quantification of SMase 
and β-glucocerebrosidase (β-GCase) mRNA expression levels performed using real-time PCR. 
Additionally, three dimensional cultured skin was incubated with SM-L and the β-GCase 
inhibitor conduritol B epoxide (CBE) and the ceramide content determined by high performance 
thin layer chromatography.  
Results: We observed generation of ceramide NS after reaction of SM-L and SMase. However, 
the other ceramide classes were not detected. Notably, SMase and β-GCase mRNA expression 
levels were significantly increased in cells of the skin model following application of SM-L. 
The levels of ceramides NS, NP, AS and AP were decreased by treatment with CBE. However, 
only ceramide NS was significantly increased by treatment with CBE and SM-L in combination.  
Conclusion: These findings indicate that application of SM-L to cultured skin upregulates the 
expression of SMase and β-GCase and increases ceramide content. 
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Introduction 
The skin comprises the epidermal and dermal layers, which together acts as a barrier, 
protecting the body from physical, chemical and microbial damage. The stratum corneum is the 
outer layer of the epidermis and comprises keratinocytes and intercellular lipids. The 
intracellular lipids of the stratum corneum include ceramide, cholesterol, fatty acids and 
cholesterol esters. These lipids adopt a lamellar structure to perform the barrier function. 
Intracellular lipids —ceramide in particular play the most important role in the barrier function 
of the stratum corneum [1-4]. 
Ceramide species are generated through either the glucosylceramide (GlcCer) pathway or the 
sphingomyelin (SM) pathway. Generally, ceramides NS and AS are synthesized from 
sphingomyelin, while all ceramide species are synthesized from glucosylceramide [5,6]. A 
lack of various sphingolipids, such as ceramide, or a deficiency of sphingolipid metabolic 
enzymes can cause diseases including Niemann-Pick disease and Gaucher’s disease [7, 8].  
	 Here we focus on the precursors of ceramide—GlcCer and SM—to elucidate the mechanism 
controlling increased ceramide levels in the skin. We have previously reported that the 
application of GlcCer-based liposomes (GlcCer-L) to a three-dimensional cultured human 
epidermis model (Labcyte Epi-Model) increased ceramide AS content [9]. Moreover, the 
application of sphingomyelin-based liposomes (SM-L) to a three-dimensional cultured human 
epidermis model increased levels of ceramides NS, NP, AS and AP [10]. However, why the 
application of SM-L induced an increase in not only ceramides NS and AS but also ceramides 
NP and AP in the Labcyte Epi-Model is unknown.  
In this study, we prepared SM-L and applied them to a three-dimensional cultured human 
epidermis model to clarify the influence of SM-L on ceramide metabolic enzymes on three- 
dimensional cultured human epidermis. 
 
Materials and Methods 
Cells 
LabCyte Epi-Model 6D and culture medium were obtained from Japan Tissue Engineering 
Co. Ltd. (Gamagori, Aichi, Japan).  
Reagents 
Sphingomyelin was purchased from NOF Co. Ltd. (Tokyo, Japan). Sphingomyelinase from 
Bacillus cereus was obtained from Sigma Aldrich (St. Louis, MO, USA). Hydroxy ceramide 
and non-hydroxy ceramide were purchased from Matreya (Pleasant Gap, PA, USA). Ceramides 
NP and AP were obtained from Evonik (Essen, Germany). L-ascorbic acid phosphate 
magnesium salt n-hydrate, chloroform, isopropyl alcohol, ethanol, methanol and acetic acid 
were purchased from Wako Pure Chemical Co. Ltd. (Osaka, Japan). Phosphate buffered saline 
(PBS), RNA iso Plus, PrimeScript® RT reagent Kit and SYBR® Premix Ex Taq™ were 
purchased from Takara Bio Inc. (Kusatsu, Shiga, Japan). Conduritol B epoxide (CBE) was 
obtained from Santa Cruz Biotechnology Inc. (Dallas, TX, USA). 
 
Preparation of sphingomyelin-based liposomes (SM-L) 
SM-L were prepared using the thin-layer film method and the freezing and thawing method. 
Briefly, sphingomyelin was dissolved in chloroform, dried under reduced pressure and the 
thin-layer film hydrated with PBS. The multi-lamella vesicles were freeze-thawed using liquid 
nitrogen and then extruded through polycarbonate membrane filters (pore size 100 nm; 
Nuclepore, Whatman, GE Healthcare Life Sciences, Buckinghamshire, UK). Finally, the SM-L 
were ultracentrifuged at 4 °C, 230,000 × g for 15 min (himac CS120GX II, Hitachi Ltd., Tokyo, 
Japan). The liposomal pellets were resuspended in PBS. 
 
Determination of the ceramide class produced by sphingomyelin-based liposomes 
Sphingomyelinase (SMase) from Bacillus cereus (1 U) was added to 10 mg/mL of SM-L and 
incubated at 37 °C for 24 h. Ceramides were developed using high-performance thin layer 
chromatography (HPTLC). Samples were developed twice with chloroform:methanol:acetic 
acid (190:9:1 v/v/v). The various ceramides were visualized by treatment with a 10% CuSO4, 
8% H3PO4 aqueous solution, and heated to 180 °C for 10 min. The amount of ceramide present 
was quantitatively determined using a densitometer. 
 
Application of SM-L to LabCyte Epi-Model  
The three-dimensional cultured human epidermis model was cultured at 37 °C in a 5% CO2 
atmosphere. SM-L (10 or 30 mg/mL) was applied to the stratum corneum side of the 
three-dimensional cultured human epidermis model followed by incubation at 37 °C for 7 days. 
Medium was changed every day (1 mM CBE as an inhibitor of β-glucocerebrosidase (β-GCase) 
was dissolved in the medium where indicated). After 7 days, the medium containing ascorbic 
acid was exchanged for enhanced keratinization medium for 24 h.  
 
Lipid extraction 
Lipids in the three-dimensional cultured human epidermis model were extracted according to 
the methods of Bligh and Dyer [11]. Briefly, the skin was dissolved in a chloroform:methanol 
(2:1 v/v) solution and sonicated using a probe-type sonicator (Advanced Sonifier Model 250A, 
Branson, Danbury, CT, USA; 50 W, 10 min). The extracted lipid solution was dried under N2 
gas, and dissolved in a chloroform:methanol (2:1 v/v) solution. The presence of the various 
ceramides was determined by HPTLC as described above.  
 
Real-time PCR 
SM-L was applied to the stratum corneum side of the three-dimensional cultured human 
epidermis model followed by a 24 h incubation at 37 °C. Total RNA was then extracted using 
RNAiso Plus. cDNA was synthesized from total RNA by reverse-transcription using a Prime 
Script™ reagent kit. Real-time PCR was performed using SYBR Premix Ex Taq™ and the Step 
One Plus ™ Real-Time PCR System (Applied Biosystems, Foster City, CA, USA).  
 
Results 
Observation of the various ceramide classes produced by sphingomyelin-based liposomes 
Figure 1 shows the various ceramides isolated from SM-L by HPTLC. Generally, ceramides 
NS and AS are synthesized from sphingomyelin, while all ceramide species are 
synthesized from glucosylceramide [5-7]. After the reaction of SM-L with SMase, ceramide 
NS was detected, however, the other ceramide classes were not observed. 
 
Figure 1 
 
Expression of β-GCase and SMase mRNA  
SM and GlcCer are metabolized to ceramide by SMase and β-GCase respectively [12-14]. 
SM-L (10 or 30 mg/mL) was applied to the stratum corneum side of the three-dimensional 
cultured human epidermis model for 24 h. The mRNA expression levels of both β-GCase and 
SMase increased after application of 10 and 30 mg/mL SM-L (p = 0.06 and p < 0.05, 
respectively)  
 
Figure 2 
 
The ceramide content of the three-dimensional cultured human epidermis model changes 
following application of SM-L and treatment with β-GCase inhibitor 
One mM of the β-GCase inhibitor CBE [15], with or without 10 mg/mL SM-L, was applied to 
the stratum corneum side of the three-dimensional cultured human epidermis model for 7 days. 
The contents of ceramides NS, NP, AS and AP were all decreased following treatment with CBE 
(without SM-L; Fig. 3). However, ceramide NS was significantly increased (p < 0.05) after 
treatment with CBE and application of SM-L. The levels of other ceramides were also slightly 
increased compared with the CBE treatment group, but these increases were not significant). 
 
Figure 3 
 
Discussion 
We have previously reported that the application of various sizes of SM-L to a three- 
dimensional cultured skin model can increase the content of ceramides NS, NP, AS and AP [10]. 
However, only ceramides NS and AS are synthesized from sphingomyelin [5]. In this study, 
we prepared SM-L and applied them to the Labcyte Epi-Model to characterize the influence of 
SM-L on ceramide metabolic enzymes in the three-dimensional cultured human epidermis. First, 
mixtures of SM-L and Bacillus cereus derived SMase were developed by HPTLC. Only 
ceramide NS was generated from SM-L (Fig. 1). Generally, ceramides NS and AS are 
synthesized from sphingomyelin, while other ceramide species are synthesized from GlcCer 
[5,6]. However we have previously reported that application of SM-L to the Labcyte Epi-Model 
increased levels of ceramides NS, NP, AS and AP. These finding suggest that SM affects not 
only SMase but also another factor. We next applied SM-L to the Labcyte Epi-Model and 
measured levels of β-GCase and SMase mRNA expression. Both were increased 24 h after 
application of 30 mg/mL SM-L (Fig. 2). This indicates that application of SM-L induced 
expression of both SMase (a SM metabolic enzyme) and β-GCase (a GlcCer metabolic 
enzyme). 
Finally, we added the β-GCase inhibitor CBE to the medium [16] and applied SM-L to the 
Labcyte Epi-Model. Ceramides NS, NP and AS contents in the Labcyte Epi-Model were 
significantly decreased compared with control group following treatment with CBE. 
Additionally, ceramide AP content was decreased compared with the control group by treatment 
with CBE (Fig. 3). Contrastingly, ceramide NS content was significantly increased following 
treatment with CBE and SM-L compared with the CBE-alone treatment group. Additionally, 
other ceramide species were increased compared with the CBE treatment group though these 
changes were not significant. These findings suggest that SM was metabolized to ceramide NS. 
Furthermore, SM may regulate the expression levels of SMase and β-GCase. This suggests that 
other ceramide species were produced following SM application. Our findings suggest that 
SMase and β-GCase expression levels were upregulated and ceramide content was subsequently 
increased following application of SM-L to the three-dimensional cultured skin epidermis model. 
Therefore, the application of SM-L to skin influences the ceramide metabolism pathway. 
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Figure captions 
Fig. 1 The HPTLC pattern of SM-L and SM-L + SMase mixtures. 
 
Fig. 2 mRNA expression levels of SMase (a) and β-GCase (b) after 24 h application of 10 or 30 
mg/mL SM-L to three dimensional cultured epidermis. Data represent means ± SD (n = 3).  
*p < 0.05 versus control, Dunnet test 
 
Fig. 3 Ceramide NS (a), NP (b), AS (c), AP (d) contents in the three dimensional cultured 
epidermis after application of 10 mg/mL SM-L and treatment of 1 mM β-GCase inhibitor. 
Ten mg/mL SM-based liposomes were applied to the stratum corneum (SC) side for 7 days. 
Data represent means ± SD of three experiments. *p < 0.05, ***p < 0.001, Tukey’s test 
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